Story

Genhouse Bio Refiles for Hong Kong IPO Following $80M Upfront Payment from Gilead

ENTHMSVIIDZHZH-TWJAKOHI
Aug 9, 20262 min read
Genhouse Bio Refiles for Hong Kong IPO Following $80M Upfront Payment from Gilead
Text size
Background

Chinese oncology drug developer Genhouse Bio (Suzhou) Co., Ltd. has refiled for an initial public offering on the Hong Kong Stock Exchange, according to a prospectus submitted on August 7. The move is supported by a significant financial turnaround, driven by a lucrative licensing deal with U.S. pharmaceutical giant Gilead Sciences.

Gilead Deal Transforms Financials

Genhouse Bio reported a dramatic surge in revenue to CNY 558 million (approx. $77 million) for the first five months of the year, a stark contrast to the full-year revenues of CNY 4.69 million and CNY 1.27 million in the two preceding years. The company's prospectus attributes this growth primarily to a global licensing agreement for its synthetic lethality drug candidate, GH31.

The deal with Gilead, finalized in February, included a non-refundable upfront payment of $80 million. This influx of capital enabled the company to swing from significant annual losses to profitability. For the five-month period, Genhouse Bio posted a net profit of CNY 355 million, reversing net losses of CNY 152 million and CNY 144 million recorded in the previous two fiscal years.

Strategic Focus on Oncology Pipeline

Founded in 2014, Genhouse Bio focuses on developing targeted cancer therapies centered on the RAS signaling pathway and synthetic lethality mechanisms. According to the filing, its pipeline consists of eight drug candidates, including four in clinical stages and one that has received Investigational New Drug (IND) approval from both U.S. and Chinese regulators.

Sample IUX Markets – In-articleAd

Beyond the Gilead partnership, the company has other key collaborations:

  • A 2020 agreement granted HUYABIO International exclusive rights to develop and commercialize its SHP2 inhibitor, GH21, outside of Greater China in a deal potentially worth up to $282 million.
  • The company is also engaged in clinical supply and joint therapy development agreements with AstraZeneca and Shanghai Zhengda Tianqing Pharmaceutical.

Market Outlook and IPO Details

Genhouse Bio's strategic focus is on a rapidly growing segment of the pharmaceutical market. Citing data from China Insights Consultancy, the prospectus notes that the global market for synthetic lethality drugs is projected to expand from $4.8 billion in 2025 to $17.4 billion by 2033.

This is the company's second attempt to list on the HKEX main board, following an initial application in January. Huatai International is acting as the sole sponsor for the proposed listing.

Read next

More on Stocks
Back to latest news

LATEST